File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Counteraction of underfeeding-induced inhibition of mammary tumor growth in rats by prolactin and estrogen administration

TitleCounteraction of underfeeding-induced inhibition of mammary tumor growth in rats by prolactin and estrogen administration
Authors
Issue Date1983
PublisherSociety for Experimental Biology and Medicine. The Journal's web site is located at http://www.ebmonline.org/
Citation
Proceedings Of The Society For Experimental Biology And Medicine, 1983, v. 173 n. 1, p. 159-163 How to Cite?
AbstractThe purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Sprague-Dawley female rats were fed half of the complete diet consumed daily by ad libitum fed controls, beginning 1 week before daily injection of estradiol benzoate (EB) or/and HAL for 3 weeks. Body weight, mammary tumor number, and mammary tumor diameter were measured at weekly intervals, and at the end of the 3 weeks blood was collected for assay of serum PRL. Full-fed (FF) control rats showed an increase by the end of 3 weeks in average body weight, mammary tumor number, and mammary tumor size whereas half-fed (HF) rats showed a significant decrease in average body weight, tumor number, and tumor size, and serum PRL concentrations when compared with these parameters in FF rats. Administration of EB to the HF rats partially prevented loss of mammary tumor size and significantly increased serum PRL levels over those of HF or FF control rats. Injection of HAL or the combination of HAL and EB completely prevented the decrease in mammary tumor number and size in the HF rats. These results suggest that regression in number and size of established mammary tumors in HF rats during a 3-week period is due primarily to a decrease in secretion of estrogen and PRL, the two hormones essential for mammary tumor growth in rats.
Persistent Identifierhttp://hdl.handle.net/10722/178421
ISSN
2002 Impact Factor: 2.714
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, FCen_US
dc.contributor.authorAylsworth, CFen_US
dc.contributor.authorMeites, Jen_US
dc.date.accessioned2012-12-19T09:47:37Z-
dc.date.available2012-12-19T09:47:37Z-
dc.date.issued1983en_US
dc.identifier.citationProceedings Of The Society For Experimental Biology And Medicine, 1983, v. 173 n. 1, p. 159-163en_US
dc.identifier.issn0037-9727en_US
dc.identifier.urihttp://hdl.handle.net/10722/178421-
dc.description.abstractThe purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Sprague-Dawley female rats were fed half of the complete diet consumed daily by ad libitum fed controls, beginning 1 week before daily injection of estradiol benzoate (EB) or/and HAL for 3 weeks. Body weight, mammary tumor number, and mammary tumor diameter were measured at weekly intervals, and at the end of the 3 weeks blood was collected for assay of serum PRL. Full-fed (FF) control rats showed an increase by the end of 3 weeks in average body weight, mammary tumor number, and mammary tumor size whereas half-fed (HF) rats showed a significant decrease in average body weight, tumor number, and tumor size, and serum PRL concentrations when compared with these parameters in FF rats. Administration of EB to the HF rats partially prevented loss of mammary tumor size and significantly increased serum PRL levels over those of HF or FF control rats. Injection of HAL or the combination of HAL and EB completely prevented the decrease in mammary tumor number and size in the HF rats. These results suggest that regression in number and size of established mammary tumors in HF rats during a 3-week period is due primarily to a decrease in secretion of estrogen and PRL, the two hormones essential for mammary tumor growth in rats.en_US
dc.languageengen_US
dc.publisherSociety for Experimental Biology and Medicine. The Journal's web site is located at http://www.ebmonline.org/en_US
dc.relation.ispartofProceedings of the Society for Experimental Biology and Medicineen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBody Weight - Drug Effectsen_US
dc.subject.meshEstradiol - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHaloperidol - Administration & Dosageen_US
dc.subject.meshMammary Neoplasms, Experimental - Etiology - Metabolism - Physiopathologyen_US
dc.subject.meshNutrition Disorders - Complicationsen_US
dc.subject.meshProlactin - Administration & Dosage - Blooden_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Inbred Strainsen_US
dc.titleCounteraction of underfeeding-induced inhibition of mammary tumor growth in rats by prolactin and estrogen administrationen_US
dc.typeArticleen_US
dc.identifier.emailLeung, FC: fcleung@hkucc.hku.hken_US
dc.identifier.authorityLeung, FC=rp00731en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid6856617-
dc.identifier.scopuseid_2-s2.0-0020622071en_US
dc.identifier.volume173en_US
dc.identifier.issue1en_US
dc.identifier.spage159en_US
dc.identifier.epage163en_US
dc.identifier.isiWOS:A1983QQ01000026-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLeung, FC=7103078633en_US
dc.identifier.scopusauthoridAylsworth, CF=6603910740en_US
dc.identifier.scopusauthoridMeites, J=7101645729en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats